.svg)
Solid IO joins the Bayer Co.Lab community
The Co.Lab Berlin membership gives us a new way to stay close to the pharmaceutical industry as we develop new approaches for personalized cancer care.
As we build new approaches for personalized cancer care, starting with immuno-oncology, staying close to pharmaceutical and biotech teams developing new therapies is important. It helps us understand the scientific and translational challenges they face and where new technologies can create the most value in drug development.
Through Bayer Co.Lab Berlin, we look forward to engaging with Bayer experts, other companies in the Co.Lab community and the wider life science ecosystem. For us, it is another important connection to the people and organizations we want to stay close to as we build Solid IO.
– Noora Hujala, CEO, co-founder
Bayer Co.Lab is Bayer’s global network of life science incubators, bringing together early-stage companies with industry expertise, mentorship and global networks. With locations across Europe, North America and Asia, Co.Lab supports emerging life science companies developing new technologies and approaches for healthcare.
A warm thank you to the Bayer Co.Lab Berlin team for welcoming us into the community!
Shape the future of cancer care
Join us in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.